FUSE-AI supports German pharmacies in digitization

Xlife Sciences AG / Keyword(s): Miscellaneous
FUSE-AI supports German pharmacies in digitization
04.07.2022 / 07:01

Xlife Sciences’ (SIX: XLS) project company FUSE-AI has been appointed as a strategic partner in the field of digitization by the pharmacy associations and federations of all 16 German federal states. FUSE-AI and the service provider GEDISA (Gesellschaft für digital Services der Apotheken), which is owned by these associations and federations, have agreed on a close and cooperative cooperation for this purpose.

Within this collaboration, various services will be conceptualized and developed based on artificial intelligence (AI), which will lead to an improvement in the quality of care in the pharmacy sector. These services include, for example, analysis tools – especially in the context of early detection and elimination of supply bottlenecks – but also support systems in the context of the various service offerings at the physical points of sale of pharmacies.

Matthias Steffen, CEO of FUSE-AI, says: “We are pleased to be able to support the teams in the pharmacies on site in their digital workflows and thus actively contribute to improving the quality of the drug supply. To that end, we are providing GEDISA with our proven AI backbone, which has been continuously refined over the past four years to form the foundation for the AI-enabled software solutions we will develop.”

Sören Friedrich, CEO of GEDISA notes, “The guiding principle of FUSE-AI is to provide medical professionals with a second opinion on diagnosis through the use of AI to increase the medical quality of medical services. GEDISA’s ambition for the collaboration is to leverage and implement this experience for the benefit of pharmacists.”

Financial calendar

Zürcher Kapitalmarkt Conference 2022 September 15, 2022

Investora 2022 Conference Zurich 21/22 September 2022

Half year results 2022 September 28, 2022


Information for journalists: IRF Reputation AG, Valentin Handschin, [email protected]

Investor Information: Xlife Sciences AG, Dennis Lennartz, [email protected]

Xlife Sciences AG

Talacker 35

8001 Zurich

Phone: +41 44 385 84 60

E-mail address: [email protected]

internet: www.xlifesciences.ch

ISIN: CH0461929603


Exchange: SIX Swiss Exchange, Zurich

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company that focuses as an incubator and accelerator on the value development and commercialization of promising research projects of universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The aim is to bridge research and development into the healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of Technology Platforms, Biotechnology/Therapies, Medical Technology and Artificial Intelligence/Digital Health to the next stage of development and participates in their subsequent implementation. For more information visit www.xlifesciences.ch


Some of the information in this press release contains forward-looking statements. Readers are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results could differ materially from those in the forward-looking statements due to various factors. Xlife Sciences assumes no obligation to publicly update or revise any forward-looking statements.

End of media report

Leave a Comment

Your email address will not be published.